Charter Medical, a division of Lydall, Inc., has announced that its 510(k) cleared CELL-FREEZE® cryogenic storage containers have been approved by Dana-Farber Cancer Institute in Boston, Massachusetts.

CELLFREEZE® was designed for peripherally derived stem cells and used for cryogenic temperature applications as low as -196˚c for storage, preservation, and transfer.

Dana-Farber Cancer Institute, a national leader in adult and pediatric cancer care and research, will be using CELLFREEZE® for stem cell applications.

Peter Ferris, President of Charter Medical commented, “We are pleased Dana-Farber Cancer Institute, a world class cancer research centre, selected CELL-FREEZE® for stem cell clinical applications. We are encouraged by market acceptance of CELL-FREEZE® and currently have our product being evaluated at over 30 stem cell research centres across North America.”